Lipid lowering therapy in patients with atherosclerotic cardiovascular diseases: Which matters in the real world? Statin intensity or low-density lipoprotein cholesterol level? ‒ D...

by Yen-Ting Yeh, Wei-Hsian Yin, Wei-Kung Tseng, Fang-Ju Lin, Hung-I Yeh, Jaw-Wen Chen, Yen-Wen Wu, Chau-Chung Wu, Taiwanese Secondary Prevention for Patients with AtheRosCLErotic Disease (T-SPARCLE) Registry Investigators
Published 2017-01-01

Prognostic effect of high-density lipoprotein cholesterol level in patients with atherosclerotic cardiovascular disease under statin treatment

by Yi-Heng Li, Wei-Kung Tseng, Wei-Hsian Yin, Fang-Ju Lin, Yen-Wen Wu, I-Chang Hsieh, Tsung-Hsien Lin, Wayne Huey-Herng Sheu, Hung-I Yeh, Jaw-Wen Chen, Chau-Chung Wu, Taiwanese Secondary Prevention for Patients with AtheRosCLErotic Disease (T-SPARCLE) Registry Investigators
Published 2020-12-01

Determinants for achieving the LDL-C target of lipid control for secondary prevention of cardiovascular events in Taiwan.

by Li-Ting Ho, Wei-Hsian Yin, Shao-Yuan Chuang, Wei-Kung Tseng, Yen-Wen Wu, I-Chang Hsieh, Tsung-Hsien Lin, Yi-Heng Li, Lien-Chi Huang, Kuo-Yang Wang, Kwo-Chang Ueng, Ching-Chang Fang, Wen-Harn Pan, Hung-I Yeh, Chau-Chung Wu, Jaw-Wen Chen, Taiwanese Secondary Prevention for patients with AtheRosCLErotic disease (T-SPARCLE) Registry Investigators
Published 2015-01-01